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Abstract: Background: Clinical treatment of heart failure is still suffering from limited efficacy 
and unfavorable side effects. The recently developed group of agents, the myosin motor activa-
tors, act directly on cardiac myosin resulting in an increased force generation and prolongation 
of contraction. The lead molecule, omecamtiv mecarbil is now in human 3 stage. In addition to 
the promising clinical data published so far, there are new in vitro results indicating that the ef-
fect of omecamtiv mecarbil on contractility is rate-dependent. Furthermore, omecamtiv mecarbil 
was shown to activate cardiac ryanodine receptors, an effect that may carry proarrhythmic risk.  
Methods: These new results, together with the controversial effects of the drug on cardiac oxy-
gen consumption, are critically discussed in this review in light of the current literature on ome-
camtiv mecarbil.  
Results: In therapeutically relevant concentrations the beneficial inotropic effect of the agent is 
not likely affected by these new results - in accordance with the good clinical data. At su-
pratherapeutic concentrations, however, activation of cardiac ryanodine receptors may increase 
arrhythmia propensity, and the stronger effect on diastolic than systolic cell shortening, ob-
served at higher pacing frequencies, may decrease or offset the inotropic effect of omecamtiv 
mecarbil.  
Conclusion: Further studies with definitely supratherapeutical concentrations of omecamtiv 
mecarbil should be designed to map the actual risk of these potentially harmful side-effects. 
Keywords: Heart failure, inotropic agents, myosin activators, Omecamtiv mecarbil, Ryanodine receptor, Cytosolic 
Ca2+. 
1. INTRODUCTION  
The principles of therapy of heart failure are con-
tinuously changing, since all conventional positive 
inotropic strategies, including the application of cardiac 
glycosides, β-adrenergic agonists, phosphodiesterase 
inhibitors, ryanodine receptor stabilizers and Ca2+ sen-
sitizers, are burdened by more or less serious side-
effects. Some of these agents, like cardiac glycosides, 
β-adrenergic agonists and phosphodiesterase inhibitors, 
are strongly proarrhythmic - partially because of the  
 
*Address correspondence to this author at the Department of Physi-
ology, University of Debrecen, H-4012 Debrecen, Hungary;  
Tel: +36-52255575; Fax: +36-52255116;  
E-mail: almassy.janos@med.unideb.hu 
concomitant Ca2+ overload, resulting in delayed after-
depolarizations [1-3]. Furthermore, the incidence of 
early afterdepolarizations is also increased by β-
receptor agonists and phosphodiesterase inhibitors due 
to the inward shift in transmembrane ion currents in 
response to elevated cAMP levels [4, 5]. Another 
common unfavorable effect of β-adrenergic agonists 
and phosphodiesterase inhibitors is the increased oxy-
gen demand of cardiac muscle, largely ascribed to the 
increased rate of Ca2+ cycling, further damaging the 
poor metabolic conditions of the failing heart [6]. The 
concept of stabilization of cardiac ryanodine receptors 
(RyR-2) is based on the pathologic leakiness of RyR-2 
leading to diastolic Ca2+ leak from the sarcoplasmic 
reticulum (SR) [7, 8]. This may strongly compromise 
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the pump function of the heart due to the increased dia-
stolic Ca2+ level combined with the reduced Ca2+ con-
tent of the SR, resulting in diastolic and systolic failure, 
respectively. Ryanodine receptor stabilizers, such as 
Rycal, K201 and JTV519, improve the contractile per-
formance by reducing diastolic Ca2+ leakage and de-
crease the energy demand of cardiac muscle [9, 10]. 
Here, it should be mentioned that the opposite strategy, 
i.e. pharmacological activation of RyR-2, has also been 
suggested to treat heart failure. 
An alternative way to support cardiac contractility is 
to enhance the efficacy of the Ca2+ signal. In this case 
less Ca2+ is required to generate a given tension, conse-
quently less energy has to be wasted for accumulation 
of Ca2+ into internal stores or pumping it out of the cell 
[11]. Ca2+ sensitizer drugs improve the mechanical per-
formance of cardiac muscle by increasing the affinity 
of troponin C to Ca2+ without increasing substantially 
the oxygen consumption of the heart [12, 13]. In ab-
sence of increased Ca2+ cycling, elevated arrhythmia 
incidence is not anticipated with these agents [14]. The 
most serious side-effect of Ca2+ sensitizers is diastolic 
stiffness manifested in compromised ventricular filling 
as a consequence of hampered relaxation of myocar-
dium. From this (and only this) point of view, the 
phosphodiesterase inhibitory action of some Ca2+ sensi-
tizers, like levosimendan or pimobendan, may be 
beneficial [11, 15]. 
2. CONCEPT OF MYOSIN ACTIVATION: OME-
CAMTIV MECARBIL AND ITS MECHANISM 
OF ACTION 
The ideal inotropic agent (1) should enhance cardiac 
pumping selectively without altering other parameters 
of cardiac function, (2) should not increase substan-
tially cardiac energy consumption, and (3) should not 
increase the incidence of cardiac arrhythmias [16]. 
Since these requirements can hardly be met with inter-
actions upstream to the contractile machinery, the 
downstream steps came into the focus of the research. 
The term “positive inotropy with a downstream 
mechanism of action” represents an alternative ap-
proach of “Ca2+ sensitization”, when Ca2+ binding af-
finity of troponin C in not altered; in contrast, the en-
hancement of the systolic force is achieved by direct 
modification of the actin-myosin cycle [14, 17-19]. 
Myosin motor activator agents differ from Ca2+ sensi-
tizers, since they increase cardiac contractility by bind-
ing to the heavy chain of the cardiac myosin molecule, 
as the selective cardiac myosin activator, omecamtiv 
mecarbil (methyl 4-[(2-fluoro-3-{[N-(6-methylpyri- 
dine-3-yl) carbamoyl]amino}phenyl)methyl] pipera- 
zine-1 -carboxylate), known also as CK-1827452. 
The first structure reported to enhance the ATPase 
activity of myosin was CK-0156636. Water solubility 
was improved and protein binding was reduced by sub-
stitution of the nitrate group for fluorine in the succes-
sor, CK-1032100. The first agent found to increase 
fractional shortening of cardiac muscle was CK-
1122534, but its selectivity was insufficient due to in-
teractions with ATP-sensitive K+ channels. In the next 
step CK-1213296 was developed. This compound 
failed to interfere with cardiac ion channels but sup-
pressed the activity of CYP 1A2. All these unfavorable 
effects were eliminated from CK-1317138, while the 
optimal effects were obtained with omecamtiv mecarbil 
(CK-1827452), which was more effective than its an-
cestor, by one order of magnitude [20, 21]. The chemi-
cal structures of these compounds, including omecam-
tiv mecarbil, are presented in Fig. (1), where the men-
tioned structural modifications are indicated by circles. 
The positive inotropic effect of omecamtiv mecarbil 
is based on its selective association to the S1 domain of 
the heavy chain of cardiac β-myosin at the site where 
the converter domain and the relay helix converge in 
the vicinity of the force-generating lever arm. The con-
secutive conformational change in the nucleotide-
binding domain of myosin results in enhanced ATPase 
activity and also in robust alterations of the mechanical 
properties of myosin head [21]. Due to the allosteric 
modulation of the nucleotide-binding domain, the inor-
ganic phosphate production, which is the rate-limiting 
step of the actomyosin cycle, is accelerated by ome-
camtiv mecarbil. As a consequence, the transition rate 
between the weakly bound and the strongly bound con-
figurations of the actin-myosin dimer also accelerates 
[22]. The resultant higher number of force-generating 
cross-bridges increases the amplitude and lengthens the 
duration of contractions [22-26]. Indeed, in vitro mo-
bility assay experiments, performed with porcine and 
human myosins, revealed that omecamtiv mecarbil re-
duced unloaded shortening velocity in accordance with 
stabilization of the “strongly bound” configuration of 
myosin heads [27-29].  
The ATPase stimulant effect of omecamtiv mecarbil 
is restricted exclusively to α and β myosin isoforms 
obtained from cardiac and slow skeletal muscles, inde-
pendently of the origin of the thin filament. Myosins 
from fast skeletal or smooth muscles are not affected, 
but slow skeletal muscles are somewhat sensitive to the 
drug. Accordingly, omecamtiv mecarbil can display 
marked effects in healthy (containing both α and β 
































































Omecamtiv mecarbil  
Fig. (1). Chemical structure of omecamtiv mecarbil and its ancestors showing the steps of drug development. 
 
myosins) as well as in failing human hearts (containing 
almost exclusively the β isoform). Due to similar rea-
sons, omecamtiv mecarbil is uniformly effective in 
atrial and ventricular myocardium [22, 23, 29-31]. 
3. CLINICAL STUDIES WITH OMECAMTIV 
MECARBIL 
Based on the robust in vitro results and in vivo ani-
mal studies, omecamtiv mecarbil was tested on 34 
healthy volunteers using transthoracic echocardiogra-
phy in a phase 1 study, designed to evaluate safety, tol-
erability and pharmacokinetic properties of omecamtiv 
mecarbil, and to determine the maximum-tolerated 
dose and plasma concentration of the drug [32]. Left 
ventricular systolic function increased significantly by 
omecamtiv mecarbil in a dose-dependent manner rang-
ing between 0.005–1 mg/kg/h doses. The correlation 
between systolic ejection time and plasma concentra-
tion was linear. The highest dose tolerated was 0.5 
mg/kg/h. At doses less than 0.5 mg/kg/h, no adverse 
effect was observed. The dose-limiting toxic effect was 
myocardial ischemia developing on the basis of the 
lengthened duration of systole on the expense of dias-
tole [32]. 
In another dose-ranging study, 45 patients with sta-
ble left ventricular systolic dysfunction were involved 
[33]. The safety and tolerability of omecamtiv mecarbil 
infusion, applied for 2, 24, and 72 hours, were moni-
tored. Left ventricular ejection time was increased by 
up to 80 ms, stroke volume by up to 9.7 ml during 
omecamtiv mecarbil infusion, these changes were ac-
companied with a moderate reduction of heart rate. On 
the other hand, both end-systolic and end-diastolic vol-
umes were compromised (by 15 and 16 ml, respec-
tively) at supratherapeutic drug concentrations. Symp-
toms of myocardial ischemia developed in two patients, 
who were attributed to the excessive prolongation of 
systolic ejection time at high plasma levels of 1.35 and 
1.75 µg/ml, corresponding to the extremely high con-
centrations of 3-4 µM [33]. 
Due to the ischemic complications observed with 
high doses of omecamtiv mecarbil, the drug was also 
studied in patients with ischemic heart disease in order 
to determine the safety and tolerability of the agent in 
this high risk group of patients [34]. The effect of 20 
hours omecamtiv mecarbil infusion was monitored us-
ing a treadmill test. Doses of omecamtiv mecarbil pro-
ducing plasma concentrations of 295 and 550 ng/ml 
(corresponding to 0.7 and 1.4 µM, respectively), suffi-
cient to increase systolic function, were well tolerated 
during physical exercise by these patients [34]. 
Pharmacokinetic properties of omecamtiv mecarbil 
were characterized in a cohort study [35]. Oral absorp-
tion half-life of the drug was 0.62 hour, the elimination 
half-life 18.5 hour, and the absolute bioavailability was 
90%. Plasma concentrations linearly correlated with 
the effects of omecamtiv mecarbil (increased stroke 
volume and systolic ejection time) in both healthy vol-
unteers and heart failure patients [35]. 
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A randomized, controlled phase 2b multicenter trial 
was performed on 606 patients to evaluate the safety 
and efficacy of omecamtiv mecarbil in individuals suf-
fering from acute heart failure [36]. Based on the 
ATOMIC-AHF study, it was concluded that omecam-
tiv mecarbil when reaching peak plasma concentrations 
of 100-500 ng/ml (corresponding to 0.25-1.25 µM) is 
well tolerated by the patients. However, the study 
failed to meet its primary end point since no significant 
effect on dyspnea could be detected (except for the 
highest-dose group). In the COSMIC-HF phase-2 mul-
ticenter trial, patients with stable symptomatic chronic 
heart failure were orally treated with omecamtiv me-
carbil for 20 weeks [37]. Patients receiving 50 mg 
omecamtiv mecarbil twice a day developed 318±129 
ng/ml peak plasma concentrations. Their systolic ejec-
tion time was increased by 25 ms and stroke volume by 
3.6 ml, while left ventricular end-systolic and end-
diastolic diameters reduced by 1.8 and 1.3 mm, respec-
tively, with the concomitant reduction of heart rate by 3 
beats/min [37]. 
In these studies, the therapeutic plasma concentra-
tions of omecamtiv mecarbil were typically in the sub-
micromolar range, but - as demonstrated above - rela-
tively high plasma concentrations ranging in the mi-
cromolar range have also been observed. It must be 
kept in mind, however, that 82% of omecamtiv mecar-
bil is bound to plasma proteins, which may make the 
comparison of clinical data with in vitro results diffi-
cult [38]. Taken all results together, omecamtiv mecar-
bil appears to be a promising, clinically effective com-
pound for the treatment of systolic heart failure sug-
gesting that the strategy of myosin motor activation 
may well be translated into the clinical practice - pro-
vided that the concentration of omecamtiv mecarbil can 
be kept at a reasonably low level. It is not fully under-
stood, however, that what can be expected in cases of 
overdose, when the plasma concentration of omecamtiv 
mecarbil may largely exceed the micromolar range. 
Although phase 2 clinical studies in patients with 
chronic heart failure yielded quite promising results 
with omecamtiv mecarbil [32, 33, 36, 37], phase 3 tri-
als are required to clarify all concerns regarding the 
consequences of overdose. The first phase 3 trial with 
omecamtiv mecarbil, the GALACTIC-HF study, 
started this year with 8000 patients, will be finished 
only in 2021 [39]. Although the efficacy, morbidity and 
mortality data based on the results of the completed 
clinical trials (including the reduction of heart size, 
heart rate and concentration of the circulating bio-
marker NT-proBNP), are very promising, the potential 
side effects of supratherapeutic omecamtiv mecarbil 
concentrations has to be handled with care before that 
time. 
4. RECENT IN VITRO AND IN VIVO RESULTS 
OBTAINED WITH OMECAMTIV MECARBIL 
4.1. Effect on Cell Shortening 
In isolated rat cardiac cells, omecamtiv mecarbil in-
creased fractional shortening and the duration of con-
traction. These effects were not associated with 
changes in cytosolic Ca2+ concentration [22]. Similar 
effects were obtained under in vivo conditions in anes-
thetized dogs and rats, where omecamtiv mecarbil dis-
played more pronounced action in the canine hearts 
[22]. However, the effects of omecamtiv mecarbil on 
cell shortening are concentration- and frequency- de-
pendent in canine ventricular cells [40]. As demon-
strated in Fig. (2), the shortening effect of 1 µM ome-
camtiv mecarbil was more pronounced on systolic than 
diastolic cell length, consequently the fractional short-
ening was increased. The opposite was observed with 
10 µM omecamtiv mecarbil, where diastolic cell length 
shortened to a greater extent than systolic cell length by 
the drug, leading to the loss of the enhancement of 
fractional shortening at pacing frequencies of 0.5 and 1 
Hz, while reduction of fractional shortening was ob-
served at 2 Hz. 
Indeed, the frequency-dependence of the action of 
omecamtiv mecarbil on sarcomere shortening was 
atypical when it was compared to that of several other 
inotropic agents. Butler et al. reported reduction of sar-
comere shortening by 1-3 µM omecamtiv mecarbil at 
high frequencies (2-3 Hz), while augmentation was 
seen only at lower ones (0.5-1 Hz) [41]. This unusual 
frequency-profile may carry important clinical implica-
tions suggesting that tachycardic patients treated with 
omecamtiv mecarbil may be prone to diastolic stiffness 
and impaired ventricular filling in case of overdose. On 
the other hand, patients with normal heart rates may 
also develop tachycardic episodes occasionally, which 
may further aggravate the mechanical performance of 
the failing heart. Some defense against tachycardia may 
be provided by omecamtiv mecarbil itself, since the 
agent was shown to slightly decrease heart rate [33, 
37]. 
An important advantage of omecamtiv mecarbil, 
compared to other inotropes, may be its limited inter-
ference with transmembrane ion currents [42], predict-
ing a low incidence of drug-induced arrhythmias based 
on direct interactions with cardiac ion channels. 
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Fig. (2). Effects of 1 and 10 µM omecamtiv mecarbil (OM) on unloaded cell shortening recorded in isolated canine ventricular 
cardiomyocytes. A: Superimposed representative analogue records showing the changes in cell length during stimulation of the 
cells at a constant pacing cycle length of 1 s. B, C: Rate-dependent effects of 1 µM (B) and 10 µM (C) omecamtiv mecarbil in 
diastolic (open symbols) and systolic (closed symbols) cell length. Data are summarized as fractional shortening in panel D. 
Symbols and bars are mean±SEM values obtained in 5 myocytes. 
 
4.2. Effect on Oxygen Consumption 
Cardiac oxygen consumption was reported to be 
close to normal in the early studies with omecamtiv 
mecarbil. In line with this, the actin-independent inor-
ganic phosphate release was not elevated [22, 23]. Al-
though this was somewhat confusing in light of the 
known enhancement of myosin ATPase activity by the 
drug (which per se predicts an elevated of oxygen de-
mand), it was concluded that the energy utilization of 
the heart can be made more effective by omecamtiv 
mecarbil [43, 44]. The mammalian heart appeared to 
tolerate myosin motor tuning well even for a longer 
period of time. Indeed, transgenic rabbits containing α 
and β isoforms of myosin at the ratio of 1:1 had normal 
lifespan and failed to develop cardiomyopathy in re-
sponse to overdrive - in contrast to the hearts of simi-
larly handled normal littermates [45, 46]. 
However, in a recent work of Bakkehaug et al. [47], 
where the effect of omecamtiv mecarbil was studied on 
oxygen consumption of porcine and murine hearts, 
omecamtiv mecarbil significantly increased oxygen 
consumption under both in vivo and ex vivo conditions. 
The elevated oxygen utilization was due to the in-
creased ATPase activity of myosin, since it could be 
restored by the ATPase inhibitor 2,3-butanedione mon-
oxide. It was concluded that omecamtiv mecarbil in-
creases the ATPase activity in the resting cardiac mus-
cle as well, resulting in a significant waste of oxygen 
and impaired cardiac efficiency [47]. This might also 
contribute to the development of symptoms of angina 
reported with high, suratherapeutic doses of omecamtiv 
mecarbil [32, 33]. 
Teerlink et al. [47] questioned the validity of the 
above results of Bakkehaug et al. [47]. Their 
argumentation was based on the fact that the 
experiments of Bakkehaug et al. had been performed in 
anesthetized animals, without applying a placebo-
control group, and under conditions that might elevate 
the sympathetic activity or causing ischemic damage 
[48]. In their response, Bakkehaug et al. [49] 
maintained that their study raised serious concerns 
about the energetic effects of omecamtiv mecarbil 
reported by the Teerlink group, and argued in support 
of adequacy of the Suga pig model being applied in 
their experiments. Clearly, further independent studies 
are required to elucidate this important detail. 
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Fig. (3). Concentration dependent effects of omecamtiv mecarbil on canine single RyR-2 channels incorporated into planar 
lipid bilayers. A: Representative analogue current records displaying the activity of the channel in the presence of diastolic (100 
nM) and close to systolic (735 nM) values of cytosolic calcium. Bars at the left side indicate zero current, corresponding to 
closed channel state. B-E: Concentration dependent effects of omecamtiv mecarbil on open probability (B), opening frequency 
(C), mean open time (D), and mean closed time (E) of RyR-2 channels. Symbols and bars indicate mean±SEM values obtained 
from 6-12 experiments. 
 
4.3. Effect on Cardiac Ryanodine Receptors 
The effect of omecamtiv mecarbil on canine RyR-2 
was studied by monitoring the electrical activity of sin-
gle RyR-2 channels incorporated into planar lipid bi-
layer [50]. Omecamtiv mecarbil (1-10 µM) signifi-
cantly increased the open probability and opening fre-
quency of RyR-2. Accordingly, the mean closed time 
was markedly reduced while the mean open time mod-
erately increased, indicating that increased open prob-
ability was mainly due to the increased frequency of 
opening in the presence of omecamtiv mecarbil (Fig. 
3). These effects of omecamtiv mecarbil were fully 
reversible and were the greatest when 100 nM Ca2+ 
concentration, corresponding to the physiological dia-
stolic Ca2+ level, was applied in the cytosolic compart-
ment. Increasing the cytosolic Ca2+ to 735 nM (a value 
close to systolic Ca2+ level) resulted in an elevated 
baseline RyR-2 activity, leaving less room for the 
stimulating effect of omecamtiv mecarbil. 
Theoretically, pharmacological activation of the 
RyR-2 might be expected to enhance the contractility - 
provided that this effect is more pronounced during 
systole than diastole. Unfortunately, according to the 
results shown in Fig. (3C), the opposite was the case, 
since the opening frequency increased several-fold by 1 
µM omecamtiv mecarbil in the presence of 100 nM 
cytosolic Ca2+, while only negligible effect was ob-
served in the presence of 735 nM Ca2+. 
Elevation of open probability of RyR-2 is poten-
tially proarrhythmic because the continuous leakage of 
Ca2+ of the SR may cause afterdepolarizations resulting 
in arrhythmias. More importantly, this Ca2+ leak may 
increase diastolic Ca2+ in the fuzzy space and may de-
crease the Ca2+ content of the SR. This is unfavorable 
in terms of pumping activity - especially in a failing 
heart - and may contribute to diastolic stiffness, ob-
served occasionally with omecamtiv mecarbil under 
conditions of overdose. Since the direct stimulatory 
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action of omecamtiv mecarbil on RyR-2 was evident at 
the concentration of 1 µM, it has to be taken into ac-
count when discussing the mechanism of action as well 
as the potential side effects of the compound. 
CONCLUSION 
In this paper, the mechanism of action of the myosin 
motor activator omecamtiv mecarbil has been dis-
cussed in details. Omecamtiv mecarbil was designed to 
support the cardiac function of patients with heart fail-
ure by utilizing their unique ability to increase the 
number of force generating actomyosin cross bridges. 
The molecule is currently in human phase 3, and based 
on the previous and current preliminary clinical results, 
its further career is promising [51-54]. The above dis-
cussed concerns do not question the beneficial effects 
of omecamtiv mecarbil on the failing heart when it is 
applied at therapeutic concentrations. It must be kept in 
mind, however, that omecamtiv mecarbil is not so se-
lective and effective as it was believed to be earlier, 
because it failed to decrease the oxygen demand of the 
heart, and it may decrease rather than increase the force 
of contraction at higher heart rates, and finally, acti-
vates RyR-2 receptors as well. These effects may likely 
develop in patients with omecamtiv mecarbil overdose. 
Therefore extra care has to be taken in cases of over-
dose if the heart rate is high, since diastolic failure due 
to diastolic stiffness combined with angina may be an-
ticipated in these cases. 
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